Advertisement

Virchows Archiv

, Volume 465, Issue 2, pp 193–198 | Cite as

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma

  • Gian Franco Zannoni
  • Giuseppina Improta
  • Gaia Chiarello
  • Angela Pettinato
  • Marco Petrillo
  • Paolo Scollo
  • Giovanni Scambia
  • Filippo Fraggetta
Original Article

Abstract

Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian cancer with characteristic biological features and aggressive clinical behavior. OCCCs show a pattern of gene mutations different from other type I ovarian malignancies, notably a higher frequency of PIK3CA mutations. In low grade serous ovarian cancer, KRAS and BRAF mutations are frequent, but little data are available on the mutational status of these genes in OCCCs. To clarify this issue, we designed a clinicopathological study with the aim to establish the incidence of KRAS, NRAS, and BRAF hot spot mutations in OCCC. Between December 2006 and June 2012, 22 patients with a proven diagnosis of OCCC were admitted to our Institutions. In all cases, final diagnosis was established according to FIGO and WHO criteria. All women received complete surgical staging. The PyroMark Q24 system (Qiagen GmbH, Hilden, Germany) was used for pyrosequencing analysis of KRAS, NRAS, and BRAF hot spot regions on 2.5-μm sections of formalin-fixed paraffin-embedded tissue from primary OCCC. Pyrosequencing analysis of KRAS, NRAS, and BRAF hot spot regions revealed the presence of mutations only at codon 12 in exon 2 of KRAS in 3 of 22 (14 %) cases. We found no mutations in the hot spot regions of NRAF (exons 2, 3, 4) or BRAF (exon 15). The median age of women with a KRAS mutated OCCC was 74 years. These OCCC were unilateral FIGO stage IA lesions in two cases associated with foci of endometriosis. We conclude that in 14 % of OCCCs, a KRAS mutation occurs in codon 2 exon 2. NRAS and BRAF mutations were not found.

Keywords

Clear-cell ovarian carcinoma KRAS NRAS BRAF Hot spot mutations 

Notes

Conflict of interest

We declare that we have no conflict of interest.

References

  1. 1.
    Kurman RJ, Shih IM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433–443PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Shih IM, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511–1518PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Shih IM, Kurman RJ (2005) Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 11:7273–7279PubMedCrossRefGoogle Scholar
  4. 4.
    Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65:10602–10612PubMedCrossRefGoogle Scholar
  5. 5.
    Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ (2005) Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11:6422–6430PubMedCrossRefGoogle Scholar
  6. 6.
    Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih IM (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484–486PubMedCrossRefGoogle Scholar
  7. 7.
    Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58:2095–2097PubMedGoogle Scholar
  8. 8.
    Wu R, Zhai Y, Fearon ER, Cho KR (2001) Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 61:8247–8255PubMedGoogle Scholar
  9. 9.
    Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I, EORTC GCG and EORTC GCG Translational Research Group (2014) Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment. Int J Gynecol Cancer 24:468–77PubMedCrossRefGoogle Scholar
  10. 10.
    Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chui MH, Rosen B, Shih IM, Wang TL (2014) Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol 232:473–81PubMedCrossRefGoogle Scholar
  11. 11.
    Gilks CB, Bell DA, Huntsman D, Longacre TA, Oliva E, Soslow R, Tsuda H, Zannoni GF, Zhao C, Zhou X (2014) Ovarian tumors: clear cell tumors. In: Kurman R, Carcangiu ML, Young R (eds) World Health Organization classification of tumours: pathology and genetics of tumours of female genital organs. IARC, LyonGoogle Scholar
  12. 12.
    Heublein S, Grasse K, Hessel H, Burges A, Lenhard M, Engel J, Kirchner T, Jeschke U, Mayr D (2013) KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants. BMC Cancer 13:483PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, Haas M, Neumann J, Boeck S, Kirchner T, Heinemann V, Stintzing S (2012) The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. Int J Cancer 131:980–6PubMedCrossRefGoogle Scholar
  14. 14.
    Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A (2009) Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205:858–62PubMedCrossRefGoogle Scholar
  15. 15.
    Cho KR, Shih IM (2009) Ovarian cancer. Annu Rev Pathol 4:287–313PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS (2008) Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109:370–376PubMedCrossRefGoogle Scholar
  17. 17.
    Anglesio MS, Carey MS, Köbel M, Mackay H, Huntsman DG, Vancouver Ovarian Clear Cell Symposium Speakers (2011) Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium. Gynecol Oncol 121:407–415PubMedCrossRefGoogle Scholar
  18. 18.
    Pectasides D, Pectasides E, Psyrri A, Economopoulos T (2006) Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 11:1089–1094PubMedCrossRefGoogle Scholar
  19. 19.
    Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA (2006) Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 102:285–291PubMedCrossRefGoogle Scholar
  20. 20.
    Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584–2589PubMedCrossRefGoogle Scholar
  21. 21.
    Rauh-Hain JA, Winograd D, Growdon WB, Schorge JO, Goodman AK, Boruta DM, Berkowitz RS, Horowitz NS, Del Carmen MG (2012) Prognostic determinants in patients with uterine and ovarian clear carcinoma. Gynecol Oncol 125:376–380PubMedCrossRefGoogle Scholar
  22. 22.
    Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694–1706PubMedCrossRefGoogle Scholar
  23. 23.
    Köbel M, Reuss A, Ad B, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG, Gilks CB (2010) The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 222:191–198PubMedCrossRefGoogle Scholar
  24. 24.
    Salani R, Kurman RJ, Giuntoli R 2nd, Gardner G, Bristow R, Wang TL, Shih IM (2008) Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 18:487–491PubMedCrossRefGoogle Scholar
  25. 25.
    Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221:49–56PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Itamochi H, Kigawa J, Terakawa N (2008) Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 99:653–658PubMedCrossRefGoogle Scholar
  27. 27.
    Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5:e232PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih IM (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174:1597–1601PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678–7681PubMedCrossRefGoogle Scholar
  30. 30.
    Zannoni GF, Morassi F, Prisco MG, De Stefano I, Vellone VG, Arena V, Scambia G, Gallo D (2012) Clinicopathologic and immunohistochemical features of ovarian clear cell carcinomas in comparison with type I and type II tumors. Int J Gynecol Pathol 31:507–516PubMedCrossRefGoogle Scholar
  31. 31.
    Kajihara H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sado T, Oi H, Kobayashi H (2010) Clear cell carcinoma of the ovary: potential pathogenic mechanisms. Oncol Rep 23:1193–1203PubMedGoogle Scholar
  32. 32.
    Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Baba T, Matsui S, Murphy SK, Konishi I (2010) Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29:1741–1752PubMedCrossRefGoogle Scholar
  33. 33.
    Mandai M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J, Konishi I (2011) Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Lett 310:129–133PubMedCrossRefGoogle Scholar
  34. 34.
    Olson JM, Hallahan AR (2004) p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 10:125–129PubMedCrossRefGoogle Scholar
  35. 35.
    McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263–1284PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E, Boyd J (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90:378–381PubMedCrossRefGoogle Scholar
  37. 37.
    Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11–22PubMedCrossRefGoogle Scholar
  38. 38.
    Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, De Goeij AP, Krausz T, Flanagan AM (2004) In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 202:336–340PubMedCrossRefGoogle Scholar
  39. 39.
    Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih IM (2005) Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 65:1994–2000PubMedCrossRefGoogle Scholar
  40. 40.
    Mayr D, Hirschmann A, Löhrs U, Diebold J (2006) KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 103:883–887PubMedCrossRefGoogle Scholar
  41. 41.
    Ichikawa Y, Nishida M, Suzuki H, Yoshida S, Tsunoda H, Kubo T, Uchida K, Miwa M (1994) Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 54:33–35PubMedGoogle Scholar
  42. 42.
    Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11:321–333PubMedCrossRefGoogle Scholar
  43. 43.
    Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM (1991) K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139:777–785PubMedCentralPubMedGoogle Scholar
  44. 44.
    Caduff RF, Svoboda-Newman SM, Bartos RE, Ferguson AW, Frank TS (1998) Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. Am J Surg Pathol 22:319–326PubMedCrossRefGoogle Scholar
  45. 45.
    Amemiya S, Sekizawa A, Otsuka J, Tachikawa T, Saito H, Okai T (2004) Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability. Int J Gynaecol Obstet 86:371–376PubMedCrossRefGoogle Scholar
  46. 46.
    Willner J, Wurz K, Allison KH, Galic V, Garcia RL, Goff BA, Swisher EM (2007) Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 38:607–613PubMedCrossRefGoogle Scholar
  47. 47.
    Jones S, Wang TL, Shih IM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330:228–231PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Auner V, Kriegshäuser G, Tong D, Horvat R, Reinthaller A, Mustea A, Zeillinger R (2009) KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 9:111PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A (2013) TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol 95:235–241PubMedCrossRefGoogle Scholar
  50. 50.
    Kurman RJ, Seidman JD, Shih IM (2005) Serous borderline tumours of the ovary. Histopathology 47:310–315PubMedCrossRefGoogle Scholar
  51. 51.
    Russell SE, McCluggage WG (2004) A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 203:617–619PubMedCrossRefGoogle Scholar
  52. 52.
    Nodin B, Zendehrokh N, Sundström M, Jirström K (2013) Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Diagn Pathol 8:106PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SS, Gershenson DM, Wong KK (2013) KRAS (but not BRAF) mutations in ovarian serous borderline tumor are associated with recurrent low-grade serous carcinoma. J Pathol 231:449–56PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih IM (2014) Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. J Pathol 232:16–22PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM (2010) BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 177:1611–1617PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ (2013) Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol 130:554–559PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Gian Franco Zannoni
    • 1
  • Giuseppina Improta
    • 2
  • Gaia Chiarello
    • 1
  • Angela Pettinato
    • 3
  • Marco Petrillo
    • 4
  • Paolo Scollo
    • 5
  • Giovanni Scambia
    • 4
  • Filippo Fraggetta
    • 3
  1. 1.Department of PathologyCatholic University of the Sacred HeartRomeItaly
  2. 2.Laboratory of Clinical Research and Advanced DiagnosticsIRCCS-CROB HospitalPotenzaItaly
  3. 3.Department of PathologyOspedale CannizzaroCataniaItaly
  4. 4.Department of Obstetrics and GynecologyCatholic University of the Sacred HeartRomeItaly
  5. 5.Department of Obstetrics and GynecologyOspedale CannizzaroCataniaItaly

Personalised recommendations